MX2018006390A - Composiciones y metodos para tratar accidente cerebrovascular isquemico. - Google Patents

Composiciones y metodos para tratar accidente cerebrovascular isquemico.

Info

Publication number
MX2018006390A
MX2018006390A MX2018006390A MX2018006390A MX2018006390A MX 2018006390 A MX2018006390 A MX 2018006390A MX 2018006390 A MX2018006390 A MX 2018006390A MX 2018006390 A MX2018006390 A MX 2018006390A MX 2018006390 A MX2018006390 A MX 2018006390A
Authority
MX
Mexico
Prior art keywords
methods
ischemic stroke
formula
compositions
treating ischemic
Prior art date
Application number
MX2018006390A
Other languages
English (en)
Inventor
Elmaleh David
Original Assignee
Aztherapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aztherapies Inc filed Critical Aztherapies Inc
Publication of MX2018006390A publication Critical patent/MX2018006390A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención está dirigida a métodos de tratamiento de un accidente cerebrovascular isquémico administrando una cantidad terapéuticamente eficaz de al menos un compuesto de Fórmula I o Fórmula II a un sujeto que lo necesita, donde el compuesto tiene la Fórmula I o Fórmula II o una sal o éster de (I) o (II); donde X es OH, alcoxilo C1-C6, 18F o 19F; Y y Z se seleccionan independientemente de alquilo C1-C6, alcoxilo C1-C6, halógeno, amina C1-C6 sustituida o no sustituida, 18F, 19F o H; y n es 1, 2 o 3.
MX2018006390A 2015-11-23 2016-11-23 Composiciones y metodos para tratar accidente cerebrovascular isquemico. MX2018006390A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562258882P 2015-11-23 2015-11-23
PCT/US2016/063462 WO2017091644A1 (en) 2015-11-23 2016-11-23 Compositions and methods for treating ischemic stroke

Publications (1)

Publication Number Publication Date
MX2018006390A true MX2018006390A (es) 2019-02-14

Family

ID=58764360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006390A MX2018006390A (es) 2015-11-23 2016-11-23 Composiciones y metodos para tratar accidente cerebrovascular isquemico.

Country Status (9)

Country Link
US (2) US20180344682A1 (es)
EP (1) EP3380095B1 (es)
JP (1) JP2018538273A (es)
KR (1) KR20180081812A (es)
CN (1) CN108472275A (es)
AU (1) AU2016359674A1 (es)
CA (1) CA3005909A1 (es)
MX (1) MX2018006390A (es)
WO (1) WO2017091644A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
US10188757B2 (en) 2013-10-22 2019-01-29 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3506894B1 (en) * 2016-08-31 2023-08-23 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
WO2019017995A1 (en) 2017-07-20 2019-01-24 Aztherapies, Inc. FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN
MX2020005615A (es) * 2017-12-04 2020-11-25 Massachusetts Gen Hospital Composiciones de cromolín y métodos de las mismas.
JP2021521122A (ja) * 2018-04-09 2021-08-26 ザ ジェネラル ホスピタル コーポレイション 筋萎縮性側索硬化症および関連障害の治療のための併用療法
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276455A1 (en) * 2003-02-13 2006-12-07 Lindsberg Perttu J Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
AU2005279961B2 (en) * 2004-08-30 2010-05-13 Seo Hong Yoo Neuroprotective effect of solubilized UDCA in focal ischemic model
CA2751125C (en) 2009-01-29 2017-06-20 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9925282B2 (en) * 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2810652A3 (en) * 2009-03-05 2015-03-11 AbbVie Inc. IL-17 binding proteins
TW201036972A (en) * 2009-03-11 2010-10-16 Plexxikon Inc Compounds and uses thereof
CN104869993B (zh) * 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
CN110652495A (zh) * 2013-05-23 2020-01-07 Az治疗公司 用于递送色甘酸的方法
US10188757B2 (en) * 2013-10-22 2019-01-29 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
PT3104853T (pt) * 2014-02-10 2020-01-14 Respivant Sciences Gmbh Tratamento com estabilizadores de mastócitos para distúrbios sistémicos
EP3506894B1 (en) * 2016-08-31 2023-08-23 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases

Also Published As

Publication number Publication date
JP2018538273A (ja) 2018-12-27
EP3380095A4 (en) 2019-10-23
CA3005909A1 (en) 2017-06-01
US20180344682A1 (en) 2018-12-06
WO2017091644A1 (en) 2017-06-01
KR20180081812A (ko) 2018-07-17
CN108472275A (zh) 2018-08-31
AU2016359674A1 (en) 2018-06-14
US20220125753A1 (en) 2022-04-28
EP3380095A1 (en) 2018-10-03
EP3380095B1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
MX2018006390A (es) Composiciones y metodos para tratar accidente cerebrovascular isquemico.
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
NZ765152A (en) Amino-methyl piperidine derivative as kinase inhibitor
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12019500480A1 (en) Pyridine compound
PH12020551013A1 (en) Oxy-fluoropiperidine derivative as kinase inhibitor
PH12014502866A1 (en) Fungicidal heterocyclic carboxamides
IN2012DN05233A (es)
MY169495A (en) Pharmaceutical compositions
MX2015012427A (es) Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer.
EA201890522A1 (ru) Способ получения противогрибковых соединений
EA201991349A1 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2018001991A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
PH12017501422A1 (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
MX2016010973A (es) Compuestos de aminocarbonilcarbamato.
MX2018001925A (es) Composiciones que comprenden compuestos triciclicos heterociclicos.
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MY185971A (en) Pyranodipyridine compound
MX2014015511A (es) Compuestos fungicidas heterociclicos.
WO2018035346A8 (en) KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER
PH12019500822A1 (en) Crystalline forms of eravacycline
MX2016004963A (es) Sal y formas cristalinas de inhibidores de quinasa tipo polo-4.
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.